NeuroBo Pharmaceuticals (NRBO) Competitors $1.08 +0.05 (+4.85%) As of 10/6/2025 Add Compare Share Share Competitors Stock AnalysisChartCompetitorsEarningsFDA EventsInsider TradesOwnershipSEC FilingsTrendsBuy This Stock NRBO vs. MDBH, JFU, KFFB, BCG, GREE, CNF, JNVR, WVFC, BTOG, and SHFSShould you be buying NeuroBo Pharmaceuticals stock or one of its competitors? The main competitors of NeuroBo Pharmaceuticals include MDB Capital (MDBH), 9F (JFU), Kentucky First Federal Bancorp (KFFB), Binah Capital Group (BCG), Greenidge Generation (GREE), CNFinance (CNF), Janover (JNVR), WVS Financial (WVFC), Bit Origin (BTOG), and SHF (SHFS). These companies are all part of the "banking" industry. NeuroBo Pharmaceuticals vs. Its Competitors MDB Capital 9F Kentucky First Federal Bancorp Binah Capital Group Greenidge Generation CNFinance Janover WVS Financial Bit Origin SHF NeuroBo Pharmaceuticals (NASDAQ:NRBO) and MDB Capital (NASDAQ:MDBH) are both small-cap banking companies, but which is the better business? We will compare the two companies based on the strength of their dividends, valuation, earnings, analyst recommendations, media sentiment, profitability, institutional ownership and risk. Is NRBO or MDBH more profitable? MDB Capital's return on equity of 14.71% beat NeuroBo Pharmaceuticals' return on equity.Company Net Margins Return on Equity Return on Assets NeuroBo PharmaceuticalsN/A -189.12% -122.31% MDB Capital N/A 14.71%14.01% Which has more volatility and risk, NRBO or MDBH? NeuroBo Pharmaceuticals has a beta of -0.26, meaning that its share price is 126% less volatile than the S&P 500. Comparatively, MDB Capital has a beta of 1.05, meaning that its share price is 5% more volatile than the S&P 500. Do institutionals & insiders have more ownership in NRBO or MDBH? 1.4% of NeuroBo Pharmaceuticals shares are held by institutional investors. Comparatively, 0.4% of MDB Capital shares are held by institutional investors. 1.1% of NeuroBo Pharmaceuticals shares are held by company insiders. Comparatively, 55.5% of MDB Capital shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term. Does the media prefer NRBO or MDBH? In the previous week, MDB Capital had 2 more articles in the media than NeuroBo Pharmaceuticals. MarketBeat recorded 2 mentions for MDB Capital and 0 mentions for NeuroBo Pharmaceuticals. MDB Capital's average media sentiment score of 0.20 beat NeuroBo Pharmaceuticals' score of 0.00 indicating that MDB Capital is being referred to more favorably in the news media. Company Overall Sentiment NeuroBo Pharmaceuticals Neutral MDB Capital Neutral Do analysts prefer NRBO or MDBH? Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score NeuroBo Pharmaceuticals 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00MDB Capital 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Which has preferable valuation & earnings, NRBO or MDBH? MDB Capital has higher revenue and earnings than NeuroBo Pharmaceuticals. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioNeuroBo PharmaceuticalsN/AN/A-$12.47MN/AN/AMDB Capital$2.16M14.75$11.69M$0.566.12 SummaryMDB Capital beats NeuroBo Pharmaceuticals on 9 of the 10 factors compared between the two stocks. Get NeuroBo Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for NRBO and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding NRBO and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart NRBO vs. The Competition Export to ExcelMetricNeuroBo PharmaceuticalsPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$9.31M$805.10M$6.12B$10.65BDividend YieldN/A4.84%5.69%4.74%P/E RatioN/A1.2585.6126.85Price / SalesN/A29.47612.81135.13Price / CashN/A17.6437.7861.77Price / Book0.727.6513.256.70Net Income-$12.47M-$7.66M$3.30B$276.44M7 Day Performance14.70%30.51%4.70%3.13%1 Month Performance56.54%32.66%8.43%10.21%1 Year Performance-60.00%73.45%88.01%40.35% NeuroBo Pharmaceuticals Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)NRBONeuroBo PharmaceuticalsN/A$1.08+4.9%N/A-62.3%$9.31MN/A0.0010High Trading VolumeMDBHMDB Capital2.2723 of 5 stars$3.48-2.1%N/A-52.0%$32.30M$3.06M6.2140News CoverageShort Interest ↑High Trading VolumeJFU9F0.4949 of 5 stars$2.67+5.1%N/A-2.2%$31.43M$42.47M0.00740Negative NewsShort Interest ↑Gap DownKFFBKentucky First Federal Bancorp0.2999 of 5 stars$3.65+4.0%N/A+12.5%$29.53M$8.84M182.6460Gap DownBCGBinah Capital Group0.3111 of 5 stars$1.72+6.8%N/A-38.0%$28.56M$173.01M-14.33130Gap UpGREEGreenidge GenerationN/A$1.82+7.1%N/A+14.6%$28.53M$59.25M0.00680News CoverageCNFCNFinance2.6096 of 5 stars$4.16+3.1%N/A-75.9%$28.50M$205.99M13.40900Negative NewsGap UpJNVRJanoverN/A$16.17+5.4%N/A+258.8%$25.55M$2.10M-6.3222Gap UpHigh Trading VolumeWVFCWVS FinancialN/A$12.23+0.1%N/AN/A$23.15M$5.13M12.4720BTOGBit Origin0.1696 of 5 stars$0.38-3.1%N/A-79.7%$22.58MN/A0.0010Gap UpSHFSSHF1.1843 of 5 stars$7.16-2.2%N/A-29.6%$20.88M$12.29M2.113Short Interest ↓ Related Companies and Tools Related Companies MDB Capital Alternatives 9F Alternatives Kentucky First Federal Bancorp Alternatives Binah Capital Group Alternatives Greenidge Generation Alternatives CNFinance Alternatives Janover Alternatives WVS Financial Alternatives Bit Origin Alternatives SHF Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:NRBO) was last updated on 10/7/2025 by MarketBeat.com Staff From Our PartnersBitcoin grabs headlines, but smart money likes this tokenBitcoin grabs headlines, but smart money likes this token My research team has identified the token positio...Crypto 101 Media | SponsoredMagnificent 7 being replaced by the “Hidden 7”?BULLISH: It's time to buy this 'hidden' AI stock An award-winning stock-rating system has turned BULLISH on...Chaikin Analytics | SponsoredAn $8 trillion-dollar discovery 17,000 ft underwater A strange rock pulled from the ocean floor may hold the key to a $16 trillion resource boom. Inside it: materi...Porter & Company | SponsoredCapital Gains Tax Strategies for SeniorsCapital gains taxes can take a bite out of your retirement income—unless you have a smart strategy. From holdi...SmartAsset | SponsoredStunning new initiative unfolding in the White House?what I just learned about what’s unfolding in the White House is truly stunning… And you need to see it for...Paradigm Press | SponsoredURGENT: The Market's 3 Red Flags Are FlashingHere’s the uncomfortable truth: The smartest investors in the world are already preparing for a crash befor...StockEarnings | Sponsored$3,600 gold is nice ... but here’s what most gold bugs are missingGold just surged past $3,600, but Weiss Ratings expert Sean Brodrick says the real upside is in select gold st...Weiss Ratings | Sponsored$100 Trillion “AI Metal” Found in American Ghost TownJeff Brown recently traveled to a ghost town in the middle of an American desert… To investigate what could...Brownstone Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding NeuroBo Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share NeuroBo Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
